Supernus Pharmaceuticals SUPN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| APOKYN | $7.73M-19.4% | $9.59M-7.7% | $10.39M-19.0% | $12.82M-14.4% | $14.98M-25.5% | |
| Collaboration revenue (ZURZUVAE) | $27.64M-15.8% | $32.83M+62.8% | $20.16M— | $0— | $0— | |
| GOCOVRI | $35.24M-8.8% | $38.63M-5.4% | $40.85M+11.4% | $36.66M+19.5% | $30.69M-16.8% | |
| ONAPGO | $8.38M-5.3% | $8.84M+29.9% | $6.81M+324% | $1.6M— | $0— | |
| Other | $4.67M-2.3% | $4.77M-32.0% | $7.03M+7.5% | $6.53M-23.8% | $8.58M+23.4% | |
| Oxtellar XR | $7.42M+8.4% | $6.85M-43.0% | $12.02M+3.3% | $11.64M+14.1% | $10.2M-22.7% | |
| Qelbree | $77.84M-3.8% | $80.95M-0.6% | $81.42M+5.0% | $77.55M+19.8% | $64.75M-13.0% | |
| Royalty, licensing, and other revenues | $29.31M+41.4% | $20.73M+510% | $3.4M-54.5% | $7.46M-4.8% | $7.84M+0.9% | |
| Trokendi XR | $9.48M+13.1% | $8.38M-16.5% | $10.04M-10.3% | $11.19M-12.6% | $12.8M-13.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Supernus Pharmaceuticals break its business down?
- Supernus Pharmaceuticals (SUPN) reports total revenues by product across 9 parts — APOKYN, Collaboration revenue (ZURZUVAE), GOCOVRI, ONAPGO and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Supernus Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Supernus Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.